Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133914 | 0.84 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2CYP3A4ACHE | |
| Hydrochloric Acid SCHEMBL4241655 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MAPK1SMN1; SMN2CYP3A4ACHE | |
| SCHEMBL25239347 | 0.79 | GPR119 (0.39) | ALDH1A1MAPK1SMN1; SMN2POLBCYP2C9 | |
| SCHEMBL30496257 | 0.79 | GPR119 (0.39) | ALDH1A1MAPK1SMN1; SMN2POLBCYP2C9 | |
| SCHEMBL25297679 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPK1SMN1; SMN2POLBMEN1 | |
| SCHEMBL29384281 | 0.77 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2POLBCYP3A4 | |
| SCHEMBL473877 | 0.77 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2POLBCYP3A4 | |
| SCHEMBL11986177 | 0.76 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2POLBL3MBTL1MEN1 | |
| SCHEMBL29898229 | 0.76 | SMN1; SMN2 (1.00) | ALDH1A1MAPK1SMN1; SMN2POLBCYP3A4 | |
| SCHEMBL3340047 | 0.76 | SMN1; SMN2 (1.00) | ALDH1A1MAPK1SMN1; SMN2POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120077028-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-118055930-A | Thiadiazole derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| CN-112624966-B | Synthetic method of 2-aminomethyl-4-methyl-5-pyridine carboxylic acid | 杭州澳赛诺生物科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-112624966-A | Synthetic method of 2-aminomethyl-4-methyl-5-pyridine carboxylic acid | 杭州澳赛诺生物科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1942890-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | ALDH1A1 3358/4885MAPK1 1005/4885SMN1; SMN2 4838/4885 |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | ALDH1A1 2210/4885MAPK1 2342/4885SMN1; SMN2 2139/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | ALDH1A1 3358/4885MAPK1 1005/4885SMN1; SMN2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.